Haemonetics Corporation (NYSE:HAE) is identified as one of the 11 Best Long Term Low Risk Stocks to Invest in, despite a 9% decline in revenue reported in the Q4 earnings call. The company, based in Massachusetts, specializes in innovative medical technologies for blood and plasma collection, surgical cell salvage, and hospital transfusion services, operating globally in over 50 countries. In the Q4 2025 earnings report released on May 8, 2025, Haemonetics saw a 9% revenue decline for the quarter and a 6% decrease in fiscal 2025 due to planned transitions. Citi maintained a Hold rating and $71 price target on May 22, 2025, but on July 9, 2025, upgraded the stock to a Buy rating with a $90 price target, reflecting confidence in growth potential. Haemonetics (NYSE:HAE) offers stability with a low beta of 0.40 and projects an 11.12% EPS increase over the next five years.

Read more at Yahoo Finance: Haemonetics Builds Momentum with New Buy Rating and Growth Promise